Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Uncharacteristically quiet here for a long time.
Cathal Friel?
It's hard to know,he has committed himself to buying more shares of Open Orphan (end of June) after annual results?
Oh no! Morebgood news - no advisory.committee required!
A gigantic stride towards a big, sustained value-defining event for AMRYT - at last!
Even better news today that the FDA are giving this application priority!
It's really down to the perception of future profitability. Rightly or wrongly the market cap for Krystal
is based on the markets belief that their gene therapy/delivery systems have the potential to be highly
effective - also that they could be leveraged for multiple different skin related indications.
Krystal has a market cap of 1.5 billion without approvals or revenue.
Headline numbers for phase 3 were just OK but if you factor in pain and suffering of the patient (change of dressings etc) it should get thru. Especially since the FDA allowed Filsuvez to be used on infants.
This share won't move until there is a lot more certainty regarding FDA approvals/merger completions etc.
The market is taking nothing for granted here - maybe if the P3 results had been "out of the ballpark"
great then some value would have been factored into the SP but for now it's just wait and see.
Amazing..almost as dead as a dodo..
Amryt is an enigma!
Excellent, just had a good topup at market..
CVR's looking good!
Let's hope NY bids it up..
Yes good news.
FDA acceptance of Oleogel
Nice find - thanks for posting
Diamondstar ..this is very good data right?
I'd be thinking Chiasma will be taking marker share from the big boys?
Positive data phase 3 trial
https://finance.yahoo.com/news/chiasma-presents-positive-patient-reported-200500451.html
Another 600k showing up after the close..
590000 late reported trades today all over £1.70
Just noticed that Joe Wiley has also been shortlisted for Chief Executive of the Year Award
Amryt have been selected for the shortlist in the Breakthrough of the Year Award - stiff competition as BioNTech are also nominated and will no doubt sweep the board in a few catagories
http://www.mediscience-event.co.uk/nominations-overview/
https://finance.yahoo.com/news/chiasma-present-encore-data-mpowered-120000035.html
It's an unbelievably messy trading book..
Hard to know what's a trade or not.
The currency spread is aligning..
Getting in again here
Big late reported trades..
Huge seller out there..
https://www.smarteranalyst.com/new-blurbs/canaccord-genuity-sticks-to-their-buy-rating-for-amryt-pharma-amyt-3/
Canaccord Genuity Sticks to Their Buy Rating for Amryt Pharma (AMYT)
Catie Powers- May 14, 2021, 6:18 AM
In a report released yesterday, Michelle Gilson from Canaccord Genuity maintained a Buy rating on Amryt Pharma (AMYT), with a price target of $40.00. The company’s shares closed last Thursday at $10.96, close to its 52-week low of $10.06.
According to TipRanks.com, Gilson is a 4-star analyst with an average return of 11.6% and a 36.1% success rate. Gilson covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Sigilon Therapeutics, and Travere Therapeutics.
Currently, the analyst consensus on Amryt Pharma is a Strong Buy with an average price target of $33.50, representing a 196.5% upside. In a report issued on May 6, Maxim Group also maintained a Buy rating on the stock with a $27.00 price target.
The company has a one-year high of $15.50 and a one-year low of $10.06. Currently, Amryt Pharma has an average volume of 54.36K.
Amryt Pharma PLC is a specialty pharmaceutical company. It is focused on developing and delivering new treatments to help improve the lives of patients with rare or orphan diseases. It holds an exclusive license to sell Lojuxta (lomitapide) for adults, across the European Union and other territories including the Middle East, North Africa, Turkey and Israel. Lojuxta is used to treat a rare life-threatening disease called Homozygous Familial Hypercholesterolemia. Myalept (metreleptin) is an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients. It derives most of the revenue from the European Economic Area (EEA).